Showing results (61-70 of 190) with videos related to
Sort By:
Pageof 19
Journal of Applied Clinical Medical Physics|February 24, 2021
Radiation treatment planning study to investigate feasibility of delivering Immunotherapy in Combination with Ablative Radiosurgery to Ultra-High DoSes (ICARUS)Michelle B Rokni, Kelli B Pointer, Jonathan George, et al.Journal of the National Cancer Institute|June 22, 2023
Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinationsLilit Karapetyan, Uzoma K Iheagwara, Adam C Olson, et al.Melanoma Research|July 9, 2026
Nectin-4 as predictive biomarker of immune-related adverse event subtypes in adjuvant anti-programmed-death-1 treatment of melanomaSabrina Bruno, Andrew D Knight, Caroline J Layding, et al.JAMA Dermatology|October 17, 2014
Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockadeShirwa Sheik Ali, Allison L Goddard, Jason J Luke, et al.Science (New York, N.Y.)|January 6, 2018
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patientsVyara Matson, Jessica Fessler, Riyue Bao, et al.Journal for Immunotherapy of Cancer|April 6, 2018
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancerRandy F Sweis, Yuanyuan Zha, Lomax Pass, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2019
Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver MetastasisDouglas B Johnson, Riyue Bao, Kristin K Ancell, et al.Future Oncology (London, England)|February 26, 2019
Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world studyJason J Luke, Sameer R Ghate, Jonathan Kish, et al.Cancer Chemotherapy and Pharmacology|April 20, 2024
Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumorsClaire Miller, Roberto Sommavilla, Cindy L O'Bryant, et al.International Journal of Radiation Oncology, Biology, Physics|June 23, 2020
A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and PembrolizumabMark C Korpics, Mei-Yin Polley, Sandeep R Bhave, et al.Pageof 19